ClinicalTrials.gg
Not yet recruitingNCT07108335Updated Nov 20, 2026

Provider and Patient RCT PROMOTE

An interventional study of PROvider ReMote ObsTetric-Related Employment Education (PROMOTE) and PROvider ReMote ObsTetric-Related Employment Education (PROMOTE) in Maternal Health, Pregnancy and Employment, sponsored by Duke University. Not yet recruiting. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
404
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Research Aim 1: Determine the effectiveness of PROMOTE vs. usual care to increase patients' receipt of counseling about workplace accommodations and pregnancy. Investigators will recruit and randomize Obstetric providers to the PROMOTE intervention or usual care. The investigators will compare the frequency of EHR documented work- related counseling and adherence to employer documentation recommendations between the two study arms.

Hypothesis: Patients receiving care by a provider randomized to PROMOTE will have higher rates of documented counseling about work and pregnancy.

Research Aim 2: Determine the effectiveness of PROMOTE vs. usual care to reduce undesired wage or advancement reduction, increase accommodation requests granted, and improve maternal-infant health. The investigators will recruit a racially and socioeconomically diverse cohort of 304 pregnant patients and compare responses to surveys and qualitative interviews about work experiences and EHR-documented maternal-infant health outcomes among patients receiving care by providers randomized to PROMOTE vs. usual care.

Hypothesis: Compared to patients receiving care by providers randomized to usual care, participants receiving care by providers randomized to PROMOTE will have less undesired loss of wages and advancement, increased accommodation request granted, and improved maternal-infant health during pregnancy.

02

Conditions studied

  • Maternal Health
  • Pregnancy
  • Employment
03

In context

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Participants:

  • Pregnant patients who are 24 - 32 weeks gestation
  • Employed or unemployed and seeking paid employment

Inclusion Criteria - Providers:

  • Clinical team member (doctor, nurse, advanced practice provider, any medical assistant or administrative staff)

Exclusion Criteria - Participants:

  • Non- English language fluency
  • Unemployed with no desire to seek paid employment

Exclusion Criteria - Providers:

  • Not a clinical team member
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
404 participants (estimated)

Study arms

  • Experimental
    Receiving Patient Education

    This arm is provided with Patient Education from providers that have received training on PROMOTE.

    Other: PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)

  • No intervention
    Usual Care

    This arm has patients who receive care of a provider that was not trained on the PROMOTE curriculum.

  • Experimental
    Receiving Provider PROMOTE Training

    Providers in this arm will receive training on PROMOTE

    Other: PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)

  • No intervention
    Usual Care of Provider

    Providers in this arm will continue usual care.

Interventions

  • OtherPROvider ReMote ObsTetric-Related Employment Education (PROMOTE)

    An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.

  • OtherPROvider ReMote ObsTetric-Related Employment Education (PROMOTE)

    An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.

06

What researchers measure

Primary outcomes

  1. Frequency of EHR (electronic health record) documented work-related counseling

    Used to determine the effectiveness of PROMOTE vs. usual care to increase patients' receipt of counseling about workplace accommodations and pregnancy.

    Time frame: From enrollment to 12 weeks after birth of child

  2. Number of participants who adhere to employer documentation recommendations

    Used to determine the effectiveness of PROMOTE vs. usual care to increase patients' receipt of counseling about workplace accommodations and pregnancy.

    Time frame: From enrollment to 12 weeks after birth of child

  3. Number of participants with undesired wage or advancement reduction

    Determined by responses to surveys and qualitative interviews about work experiences.

    Time frame: From enrollment to 12 weeks after birth of baby

  4. Number of participants with accommodation requests granted

    Determined by responses to surveys and qualitative interviews about work experiences.

    Time frame: From enrollment to 12 weeks after birth of baby

  5. Number of participants with improved maternal-infant health in pregnancy

    Determined by EHR-documented maternal infant health outcomes among patients receiving care by providers randomized to PROMOTE vs. usual care.

    Time frame: From enrollment to 12 weeks after birth of baby

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 7, 2025
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Dec 2026
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Oct 1, 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07108335
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Dec 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Sarahn Wheeler, MD
Contact
sarahn.wheeler@duke.edu
919-681-5220
Kristin Weaver
Contact
kristin.weaver@duke.edu
Sarahn Wheeler, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion